Jiangsu Yahong Meditech Co., Ltd. Class A
SSSE:68817612.03
CNY
+0.33
(+2.82%)
Jiangsu Yahong Meditech Co., Ltd. Class A
SSE:688176
(Shanghai Stock Exchange)
Recent
price
12.03
P/E
ratio
- -
div
yld
0.02%
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Jiangsu Yahong Meditech Co Ltd specializes in the research, development, manufacturing, and sales of medical devices and related healthcare products. The company’s core product offerings include interventional medical devices such as cardiovascular and peripheral vascular stents, balloon catheters, guide wires, and other minimally invasive surgical instruments. It also provides diagnostic equipment and consumables used in clinical treatments. Operating primarily within the medical technology and healthcare industry, Jiangsu Yahong Meditech serves hospitals, clinics, and healthcare professionals in China and selectively in overseas markets. Founded in 2001, the company is headquartered in Jiangsu Province, China. In the last one to two years, Jiangsu Yahong Meditech has pursued business expansions through strategic partnerships and launched new product lines aimed at enhancing interventional therapy technologies. The company has augmented its research and development capabilities to support innovation in drug-eluting stents and other advanced medical device categories. It has also strengthened its domestic market presence by enhancing sales channels and increasing collaboration with leading medical institutions. These developments reflect a strategic focus on expanding technological leadership and broadening its product portfolio in the rapidly evolving medtech sector in China. Jiangsu Yahong Meditech's operations span the medical device manufacturing segment with significant emphasis on interventional cardiology and minimally invasive surgery markets. Its main markets include hospitals and specialty clinics requiring advanced therapeutic devices. The company leverages proprietary technology and complies with regulatory standards pertinent to medical devices in China. It continues to invest in innovation to meet increasing clinical demands while expanding geographically with selective international presence. The company remains privately held and operates from Jiangsu, maintaining strong research alliances and supply chain management frameworks to support growth and product quality.
Company News
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe